drugset / Trial / NCT03250338
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Timeline
- Start
- 2018-08-16
- Primary completion
- 2026-04-03
- Completion
- 2026-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crenolanib | Small molecule | — | Oral |
| Background | Cytarabine | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | G-CSF | Unknown | — | — |
| Background | Idarubicin | Small molecule | — | — |
| Background | Mitoxantrone | Small molecule | — | — |